David Giljohann, Ph.D


Dr. Giljohann is the Chief Executive Officer and director of Exicure. He has served as the CEO since November 2013 and has been on the board of directors since March 2014. 


Dr. Giljohann completed his Ph.D. in the laboratory of Dr. Chad A. Mirkin where he developed oligonucleotide-modified nanoparticles, including NanoFlare™ and Spherical Nucleic Acid (SNA™) technologies. Dr. Giljohann was named to the Endpoint News’ “Under 40s” biopharma executives list in 2018 and the Analytical Scientist’s “Top 40 Under 40 Power List” in 2014. Dr. Giljohann has also been recognized for his work with a Materials Research Society Gold Award, Baxter Innovation Award, Rappaport Award for Research Excellence, NSEC Outstanding Research Award, and as a finalist in the National Inventors Hall of Fame Collegiate Inventors Competition. 


Dr. Giljohann received his B.A. in Biology and Ph.D. in Biochemistry from Northwestern University.